Recent scientific evidence [18-22] together with the joint AHA/CDC guidelines [15], however, strongly recommends that in performing a global risk assessment for CAD, new risk factors to measure heart attack risk such as circulating markers of inflammation like C-reactive protein (CRP)should be used. The gene discussed is CRP; the disease is coronary artery disorder.